A comparison of the antiemetic efficacy of prochlorperazine and metoclopramide for the treatment of cisplatin-induced emesis: a prospective, randomized, double-blind study. 1985

B I Carr, and M Bertrand, and S Browning, and J H Doroshow, and C Presant, and B Pulone, and L R Hill

This study compared high-dose metoclopramide and prochlorperazine for their antiemetic activities in the treatment of patients with solid tumors receiving cisplatin-based cancer chemotherapy, in a prospective, double-blind fashion. Sixty patients were entered in the study, and 28 patients on each regimen were evaluable. For regimen 1, metoclopramide was given intravenously (IV) over 15 minutes at a dose of 2 mg/kg 30 minutes before, 30 minutes after, and three hours after treatment with cisplatin. In regimen 2, prochlorperazine was given IV 30 minutes before and three hours after the cisplatin; a placebo was administered at 30 minutes after cisplatin. There was no statistically significant difference between the two regimens in their antiemetic efficacies during the first three hours. For emesis that occurred from three to 24 hours after administration of cisplatin, prochlorperazine was marginally superior. The median number of emeses in the metoclopramide regimen was 2.5 (range, 0 to 10+) compared to 1.0 (range, 0 to 10+) in the prochlorperazine regimen. This is not a significant difference. The overall incidence of adverse reactions was greater in the metoclopramide regimen, with drowsiness being the most common toxicity for both antiemetic programs. Thus, IV high-dose metoclopramide and prochlorperazine are similar and effective in the management of cisplatin-induced emesis. IV prochlorperazine at 20-mg dosage is surprisingly effective.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008787 Metoclopramide A dopamine D2 antagonist that is used as an antiemetic. 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide,Cerucal,Maxolon,Metaclopramide,Metoclopramide Dihydrochloride,Metoclopramide Hydrochloride,Metoclopramide Monohydrochloride,Metoclopramide Monohydrochloride, Monohydrate,Primperan,Reglan,Rimetin,Dihydrochloride, Metoclopramide,Hydrochloride, Metoclopramide,Monohydrochloride, Metoclopramide
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D011346 Prochlorperazine A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612) Compazine,Prochlorperazine Edisylate,Prochlorperazine Edisylate Salt,Prochlorperazine Maleate,Edisylate Salt, Prochlorperazine,Edisylate, Prochlorperazine,Maleate, Prochlorperazine,Salt, Prochlorperazine Edisylate
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

B I Carr, and M Bertrand, and S Browning, and J H Doroshow, and C Presant, and B Pulone, and L R Hill
January 1991, Oncology,
B I Carr, and M Bertrand, and S Browning, and J H Doroshow, and C Presant, and B Pulone, and L R Hill
August 1993, American journal of clinical oncology,
B I Carr, and M Bertrand, and S Browning, and J H Doroshow, and C Presant, and B Pulone, and L R Hill
January 1984, Clinical pharmacy,
B I Carr, and M Bertrand, and S Browning, and J H Doroshow, and C Presant, and B Pulone, and L R Hill
January 1980, Cancer treatment reports,
B I Carr, and M Bertrand, and S Browning, and J H Doroshow, and C Presant, and B Pulone, and L R Hill
January 1991, Cancer chemotherapy and pharmacology,
B I Carr, and M Bertrand, and S Browning, and J H Doroshow, and C Presant, and B Pulone, and L R Hill
November 1988, Cancer,
B I Carr, and M Bertrand, and S Browning, and J H Doroshow, and C Presant, and B Pulone, and L R Hill
November 1985, Cancer treatment reports,
B I Carr, and M Bertrand, and S Browning, and J H Doroshow, and C Presant, and B Pulone, and L R Hill
October 1996, Anaesthesia and intensive care,
B I Carr, and M Bertrand, and S Browning, and J H Doroshow, and C Presant, and B Pulone, and L R Hill
January 1988, Cancer investigation,
B I Carr, and M Bertrand, and S Browning, and J H Doroshow, and C Presant, and B Pulone, and L R Hill
October 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!